MORRIS PLAINS, N.J., Sept. 19, 2012 /PRNewswire/ -- ElectroCore® Medical, a company dedicated to developing effective, non-invasive and non-pharmacologic therapy for serious headache conditions and bronchoconstriction, today reported that data related to its GammaCore® technology will be featured in a poster session at the European Headache and Migraine Trust International Congress (EHMTIC), being held September 20-23, 2012 in London, UK.
The study, "Trigeminal Pain is Suppressed by Non-Invasive Vagal Nerve Stimulation in a Rat Headache Model," which was led by Dr. Michael L. Oshinsky, Department of Neurology, Thomas Jefferson University, will be presented during Poster Session B, Session 4 on Friday, September 21 from 14:30 to 16:00 p.m.
"GammaCore therapy is based on strong, established medical science, as well as new insights into the importance of nerve signaling to serious conditions including cluster and migraine headaches," said Frank Amato, Chief Operating Officer of ElectroCore. "Early patient and practitioner experience is very positive. We look forward to sharing the data at EHMTIC."
GammaCore is a non-invasive, vagus nerve stimulator that produces a mild electrical signal which is transmitted to the vagus nerve through the skin. It's indicated for the acute and/or prophylactic treatment of migraine, cluster headache, and medication overuse headache (MOH) in adults. GammaCore is currently available in the European Union, South Africa, India, New Zealand, and Malaysia for the acute and/or prophylactic treatment of migraine, cluster headache, and MOH in adults. GammaCore is available in Canada for cluster headache only.
About ElectroCore Medical
ElectroCore is a healthcare company focused on neuromodulation therapies for the treatment of diseases and disorders. The company has developed effective, non-invasive, and non-pharmacologic therapies that treat or prevent symptoms of serious headache conditions, bronchoconstriction, and canine epilepsy by sending a mild electrical signal through the skin to stimulate the vagus nerve. ElectroCore currently has three commercial products on the market: GammaCore, AlphaCore®, and GammaCore VET™. The company is headquartered in Morris Plains, NJ, with international offices in Stockholm, Sweden, Hamilton, Bermuda, and Sydney, Australia. For more information, visit: http://www.electrocoremedical.com/.
SOURCE ElectroCore Medical